Nigerian Journal of Cardiology

: 2019  |  Volume : 16  |  Issue : 1  |  Page : 72--76

Noncardiac co – morbidities in elderly patients with heart failure

Ehi Judith Ogbemudia, Linda Iruobe Iyawe 
 Department of Medicine, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria

Correspondence Address:
Dr. Ehi Judith Ogbemudia
Department of Medicine, University of Benin Teaching Hospital, Benin City, Edo State


Background: The population of elderly persons with heart failure (HF) is on the increase, and HF is associated with multiple morbidities, but the common noncard'iac comorbidities have not been established. Objective: The objective of the study is to determine the common noncard'iac comorbidities in elderly patients with HF. Materials and Methods: The following data were retrieved from the HF register demographics: cause of HF, type of HF (reduced or preserved ejection fraction), and comorbidities. The comorbidities were: chronic obstructive pulmonary disease (COPD), renal dysfunction, osteoarthritis, and cerebrovascular accident (CVA). The others were: diabetes mellitus (DM), anemia, obesity, and cancer. The frequencies of these comorbidities were determined. Student's t-test and Chi-square tests were applied as appropriate. Results: There were 204 cases; the mean age was 74.73 ± 7.34 years. The frequencies of comorbidities were: DM 68 (33.3%), renal dysfunction 53 (26%), osteoarthritis 44 (21.6%), and COPD 29 (14.2%). The others were: anemia 26 (12.7%), CVA 18 (8.8%), obesity 8 (3.9%), and cancer 3 (1.5%). The prevalence of HF with reduced and preserved ejection fraction was 88 (43.1%) and 116 (56.9%), respectively. The association between the number of comorbidities and the type of HF (HF with reduced ejection fraction or HF with preserved ejection fraction) yielded a P = 0.068. Conclusion: The common noncardiac comorbidities in elderly HF patients are DM, renal dysfunction, and osteoarthritis. These conditions should be actively sought for in every elderly patient with HF for more holistic management and better prognosis.

How to cite this article:
Ogbemudia EJ, Iyawe LI. Noncardiac co – morbidities in elderly patients with heart failure.Nig J Cardiol 2019;16:72-76

How to cite this URL:
Ogbemudia EJ, Iyawe LI. Noncardiac co – morbidities in elderly patients with heart failure. Nig J Cardiol [serial online] 2019 [cited 2020 Jul 13 ];16:72-76
Available from:

Full Text


The population of elderly persons with heart failure (HF) is on the increase, and they have worse morbidity and mortality compared with the other age groups.[1] Noncardiac comorbidities are chronic diseases of other systems besides the heart which occur concomitantly with HF and contribute to its progression.[2],[3] These associations could be through shared risk factors or direct pathophysiologic links. Comorbidities influence management decisions, lower quality of life, and worsen outcomes in HF patients.[4],[5] Only 37% of hospitalizations in elderly patients with HF are related to HF.[6] Comorbidities are, therefore, a key component in the holistic management of HF and are listed in major HF guidelines.[7],[8]

In general, the prevalence and pattern of comorbidities in HF have not been extensively investigated in our locale. The etiology and precipitants of HF have been well-studied and documented.[9],[10] The comorbidities in other chronic diseases such as hypertension, chronic kidney disease (CKD), and diabetes have also been reported by Karaye et al.,[11] Fasipe et al.,[12] and Kayode et al.[13] However, the comorbidities in HF remain understudied. Van Deursen et al.[14] and Streng et al.[15] documented the burden and pattern of comorbidities in HF patients, but these studies were not in the elderly, and they were conducted in Europe. There may be racial differences.

Therefore, the common comorbidities in elderly HF patients have not been established in our locale; hence, the reason for this study. This study will facilitate early detection of common comorbidities in elderly HF patients for a more comprehensive management and better clinical outcomes. The hypothesis from preliminary clinical observations is that diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD) are the most common comorbidities in elderly patients with HF.

Therefore, the purpose of this study is to determine the most common noncardiac comorbidities in elderly patients with HF.

 Materials and Methods

This was a retrospective study conducted in the department of medicine of a tertiary health-care center. The protocol was approved by the Hospital's Research and Ethics Committee, and the study was according to the Helsinki Declaration. Data of the elderly (65 years and above) patients with HF admitted from June 2016 to May 2018 were retrieved from the HF register.

Inclusion criteria

Cases with complete data were included.

Exclusion criteria

Cases without complete data were excluded.

Definition of terms

Noncardiac comorbidities

These are chronic diseases or disorders of other systems besides the heart that occur concomitantly with HF and contribute to its progression.[3] Cardiac morbidities are primarily diseases of the heart and are the principal causes of HF. This study focused on noncardiac comorbidities because they have been shown to have a negative impact on outcomes in HF.[5]

Diabetes mellitus

DM was defined as a fasting or random blood glucose ≥126 mg/dl and ≥200 mg/dl, respectively, or active treatment with oral hypoglycemic medications or insulin.[16]

Renal dysfunction/chronic kidney disease

This was defined as an estimated glomerular filtration rate (GFR) <60 ml/min/1.73 m2 based on the modification of diet in renal disease study equation.[17]


Anemia was defined as hemoglobin level <12 mg/dl for females and 13 mg/dl for males.[18]


The presence of pain in the joints worsened by movement in addition to joint space narrowing with osteophytes formation on X-ray defined osteoarthritis. It included osteoarthritis of the knee, cervical, and lumbar spine.

Cerebrovascular accident

Cerebrovascular accident (CVA) was defined as the rapid development of focal or global disturbance of cerebral function, with symptoms lasting 24 h or longer or leading to death, with no apparent cause other than vascular. This was confirmed on cranial computed tomography.


A body mass index (BMI) of ≥30 kg/m2 defined obesity.[19]

Cancer of the breast

The presence of breast lesion with features of malignancy confirmed on histology.

Chronic obstructive pulmonary disease

COPD was defined as chronic cough with sputum production. In addition, the ratio of forced expiratory volume in 1 s to forced vital capacity of <0.8 on spirometry confirmed the diagnosis.[20]

The age, gender, weight, and height were recorded from the HF register. The other variables were the blood pressure, etiology of HF, and comorbidity. Type of HF (preserved or reduced ejection fraction) the comorbidities included anemia, CKD, COPD, DM, osteoarthritis, cerebrovascular disease, obesity, and cancer. The BMI was derived from the weight and height Wt/Ht2.[21]


Data were analyzed with a statistical package for social sciences version 20 (SPSS Inc., Chicago, IL, USA). The means and ranges of continuous variables were derived. The frequencies of cases with and without comorbidities were also derived, and the prevalence of comorbidities was determined as a percentage of the total number of cases studied. The frequencies of the different comorbidities were also determined. Student's t-test was used to compare continuous variables in two independent groups, and Chi-square test was used to determine an association between categorical variables.


There were a total of 204 cases 106 (52%) were female while 98 (48%) were male. One hundred and forty-eight (72.5%) had comorbidities while 56 (27.5%) did not have comorbidities. Among those with comorbidities, 52 (35.1%), 72 (49.3%), and 23 (15.5%) had 1, 2, and 3 comorbidities, respectively. The etiologies of HF were hypertensive heart disease (HHD), 130 (63.7%), 55 (27%) had valvular heart disease and cardiomyopathies 19 (9.3%). The prevalence of the three age groups were as follows: 65–73 years (96, 47%), 74–82 years (64, 31.4%), 83 and above (44, 1.6%). One hundred and sixteen (56.9%) had HF with preserved ejection fraction (HFpEF) whereas 88 (43.1%) had HF with reduced ejection fraction (HFrEF). [Figure 1] shows the prevalence of the various noncardiac comorbidities.{Figure 1}


The results show that majority 148 (72.5%) of the cases studied had comorbidities. This means there is a high prevalence of comorbidities in elderly patients with HF. This is not surprising because aging is associated with multiple morbidities[22], and HF is also associated with comorbidities.[23] Murad et al.[24] and Saczynski et al.[25] reported higher prevalence of comorbidities because they examined both cardiac and noncardiac comorbidities in their studies. Variation in population characteristics may also have contributed to the difference in result. The high prevalence of comorbidities in elderly HF patients is associated with a low quality of life; worse outcomes and increased health-care expenditure due to repeated hospitalizations and polypharmacy.

[Figure 1] shows that DM was the most common comorbidity with a prevalence of 68 (33.3%). DM is associated with the older adult, and it is an established cardiovascular risk factor for atherosclerotic coronary artery disease and diabetic cardiomyopathy (CMP).[26] Bos et al.[27] and Booman-De Winter et al.[28] reported a high prevalence of cardiac dysfunction in DM patients. In a similar study, Ruiz-Laiglesia et al.[29] reported CKD as the most common comorbidity in HF. This is most probably due to differences in the population studied.The coexistence of HF and DM has both prognostic and therapeutic implications. HF patients with DM have a worse prognosis compared to HF without diabetes. Insulin and thiazolidinediones have been associated with worse outcomes in HF patients. Dipeptidyl peptidase 4 inhibitors are also not recommended in HF.

Furthermore, [Figure 1] shows that renal dysfunction was the next most common comorbidity 53 (26%). After DM, renal dysfunction specifically CKD usually coexists with HF and vice versa because of the cross talk between the heart and the kidneys (cardiorenal syndrome). HF reduces renal perfusion and GFR, which activates neurohormonal systems with consequent sodium and water retention. The age-associated decline in GFR may also have contributed to this result. CKD is the single strongest predictor of outcome even beyond left ventricular ejection fraction in HF patients.[27]

Osteoarthritis of the knees, lumbar, and cervical spine constituted 44 (21.6%) of the comorbidities. The use of nonsteroidal anti-inflammatory drugs for pain in these degenerative conditions worsens HF from sodium and water retention. Other less common comorbidities were COAD 28 (13.7%), anemia 26 (12.7%), and CVA 18, (8.8%). The least prevalent morbidity was obesity 8 (3.9%) and cancers 3 (1.5%).

The results show that the causes of HF were HHD, rheumatic heart disease, and CMP, but the different cardiomyopathies (restrictive, hypertrophic, and idiopathic dilated) were grouped together because they were few. [Table 1] shows a wide range in the blood pressures, this is not surprising because the cases studied were made up of different cardiac diseases.{Table 1}

The results show that the oldest age group (83 years and above) was the least prevalent 44 (21.6%), while the majority 96 (47%) were in the age group of 65–73 years. Survival bias may explain why there were fewer cases of the older elderly. The results also show that HFrEF (116 (56.9%) was more common compared to HFpEF 88 (43.1). This is not surprising because HFpEF has been shown to be more common in the elderly. Late presentation to the hospital may explain why some had HFrEF because systolic function declines as HF progresses.

[Table 2] shows that patients with comorbidities had a significantly higher BMI compared to those without comorbidities P = 0.004. Excessive weight is a well-known cardiovascular risk factor. [Table 3] shows there is a significant association between age group and the number of comorbidities P = 0.005. This is only apparent because the sizes of the age groups were not similar. That is the younger elderly were more than, the older elderly as mentioned earlier.{Table 2}{Table 3}

The limitations in this study include the fact it was retrospective and of small sample size (pilot study). Nevertheless, it has achieved its main objective which was to determine the common noncardiac comorbidities in elderly patients with HF. There is, however, a need for a main prospective study. Implications for future research includes studies of each comorbidity subgroup for characterization of the clinical profile and cardiac function. Longitudinal studies will help determine which of these comorbidities impacts most negatively on outcomes such as hospitalizations and mortality. A similar study in the middle-aged and young would help determine whether comorbidities in the elderly differ with age group.


DM, renal dysfunction, and osteoarthritis are the most common noncardiac comorbidities in elderly patients with HF. These conditions should be actively sought for in every elderly HF patient for a more holistic management and better prognosis. DM patients should be given cardioprotective drugs beyond blood glucose lowering.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Jugdutt BI. Aging and heart failure: Changing demographics and implications for therapy in the elderly. Heart Fail Rev 2010;15:401-5.
2Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23:455-68.
3Rushton CA, Satchithananda DK, Jones PW, Kadam UT. Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis. Int J Cardiol 2015;196:98-106.
4Shaffer JA, Maurer MS. Multiple chronic conditions and heart failure: Overlooking the obvious? JACC Heart Fail 2015;3:551-3.
5Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226-33.
6Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med 2009;360:1418-28.
7Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013;62:e147-239.
8Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
9Ojji DB, Alfa J, Ajayi SO, Mamven MH, Falase AO. Pattern of heart failure in Abuja, Nigeria: An echocardiographic study. Cardiovasc J Afr 2009;20:349-52.
10Onwuchekwa AC, Asekomeh GE. Pattern of heart failure in a Nigerian teaching hospital. Vasc Health Risk Manag 2009;5:745-50.
11Karaye KM, Akintunde AA, Olusegun-Joseph A, Balarabe SA, Okunowo BO, Opadijo OG, et al. Mortality and co-morbidities among hospitalised hypertensives in Nigeria. Int Cardiovasc Forum J 2017;11:37-41.
12Fasipe OJ, Akhideno PE, Ibiyemi-Fasipe OB, Idowu A. A burden of polypharmacy and pattern of co morbidities among chronic kidney disease patients in clinical practice. AMHS 2018;6:40-1.
13Kayode OO, Odukoya OO, Odeniyi IA, Olopade OB, Fasanmade OA. Pattern of complications and co morbidities among diabetic patients in a tertiary healthcare center in Nigeria. J Clin Sci 2015;12:29-35.
14Van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L, et al. Co-morbidities in patients with heart failure: An analysis of the European heart failure pilot survey. Eur J Heart Fail 2014;16:103-11.
15Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 2018;271:132-9.
16Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97.
17Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
18World Health Organization. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968;405:5-37.
19Haslam DW, James WP. Obesity. Lancet 2005;366:1197-209.
20Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
21Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes 1985;9:147-53.
22Abdulraheem IS, Amodu MO, Salami SK, Adegboye A, Fatiregun A, Tobin-West C. Prevalence and pattern of multi-morbidity among elderly people in rural Nigeria: Implications for health care system, research and medical education. J Community Med Health Care 2017;2:1019-21.
23van der Wal HH, van Deursen VM, van der Meer P, Voors AA. Comorbidities in heart failure. Handb Exp Pharmacol 2017;243:35-66.
24Murad K, Goff DC Jr., Morgan TM, Burke GL, Bartz TM, Kizer JR, et al. Burden of comorbidities and functional and cognitive impairments in elderly patients at the initial diagnosis of heart failure and their impact on total mortality: The cardiovascular health study. JACC Heart Fail 2015;3:542-50.
25Saczynski JS, Go AS, Magid DJ, Smith DH, McManus DD, Allen L, et al. Patterns of comorbidity in older adults with heart failure: The cardiovascular research network PRESERVE study. J Am Geriatr Soc 2013;61:26-33.
26Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Eur Heart J 2013;34:2436-43.
27Bos M, Agyemang C. Prevalence and complications of diabetes mellitus in Northern Africa, a systematic review. BMC Public Health 2013;13:387.
28Booman-De Winter L, Rutten F, Cramer M. High prevalence of diastolic dysfunction in patients with type 2 diabetes. Eur J Heart Fail 2011;10:205-10.
29Ruiz-Laiglesia FJ, Sánchez-Marteles M, Pérez-Calvo JI, Formiga F, Bartolomé-Satué JA, Armengou-Arxé A, et al. Comorbidity in heart failure. Results of the Spanish RICA registry. QJM 2014;107:989-94.